S Kant Healthcare Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: S Kant Healthcare Limited Pharmaceutical Export Portfolio Dataset — 12 Products, $35.0M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

S Kant Healthcare Limited — Pharmaceutical Exporter Profile (2026) | 12 Products, $35.0M Trade | TransData Nexus

S Kant Healthcare Limited

Indian Pharmaceutical Exporter · Antimalarial & Antiparasitic Specialist · $35.0M Total Trade · DGFT Verified

S Kant Healthcare Limited is an Indian pharmaceutical exporter with a total trade value of $35.0M across 12 products in 6 therapeutic categories. Based on 946 verified export shipments from Indian Customs (DGFT) records, S Kant Healthcare Limited is the #1 Indian exporter in 2 products including Sulfadoxine, Pyrimethamine. Top exports include Artemether ($8.4M), Clotrimazole ($7.2M), Sulfadoxine ($5.2M).

S Kant Healthcare Limited — Export Portfolio & Destination Treemap

S Kant Healthcare Limited pharmaceutical export portfolio — 12 products across 6 therapeutic categories. Source: Indian Customs (DGFT).

Who is S Kant Healthcare Limited? — Company Overview & Market Position

S Kant Healthcare Limited, established on March 18, 1996, is a public unlisted company headquartered in Mumbai, Maharashtra, India. It operates under the Corporate Identification Number (CIN) U24230MH1996PLC098246. The company is a subsidiary of the SK Group, a conglomerate with a legacy in the pharmaceutical industry dating back to 1932.

The authorized capital of S Kant Healthcare Limited is ₹10 million, with a paid-up capital of ₹9.8 million. As of the latest available data, the company employs approximately 540 professionals. The registered office is located at A/3, Shivsagar Estate, North Wing, Dr. Annie Besant Road, Mumbai, Maharashtra 400018, India.

What Does S Kant Healthcare Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Artemether$8.4M 2Clotrimazole$7.2M

Product Portfolio — Top 12 by Export Value

S Kant Healthcare Limited exports 12 pharmaceutical products across 6 therapeutic categories. Market leader (#1 exporter) in 2 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Artemether	Antimalarial & Antiparasitic	$8.4M	191	0.9%	9
2	Clotrimazole	Antifungals	$7.2M	178	7.8%	4
3	Sulfadoxine	Antimalarial & Antiparasitic	$5.2M	103	9.5%	1
4	Pyrimethamine	Antimalarial & Antiparasitic	$4.3M	85	9.2%	1
5	Erythromycin	Antibiotics	$2.8M	94	3.5%	4
6	Metronidazole	Advanced Antibiotics	$2.3M	71	1.1%	13
7	Naproxen	Analgesics & Antipyretics	$1.6M	36	1.2%	15
8	Doxycycline	Antibiotics	$1.2M	45	1.0%	12
9	Nystatin	Antifungals	$964.7K	77	1.8%	11
10	Gentamicin	Antibiotics	$713.4K	22	1.4%	15
11	Miconazole	Antifungals	$253.5K	32	1.3%	14
12	Glibenclamide	Advanced Diabetes Medications	$104.7K	12	0.3%	10

S Kant Healthcare Limited exports 12 pharmaceutical products across 6 therapeutic categories with a total export value of $35.0M. The company is the #1 Indian exporter in 2 products: Sulfadoxine, Pyrimethamine. The top category is Antimalarial & Antiparasitic (50.9% of portfolio), followed by Antifungals (24.0%), indicating a concentrated portfolio with the top 5 products accounting for 79.4% of total export value.

S Kant Healthcare Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

S Kant Healthcare Limited operates a state-of-the-art manufacturing facility in Vapi, Gujarat, India. This EU-GMP certified plant spans 11 acres (approximately 45,000 square meters) and is equipped with dedicated buildings for the production of finished formulations, active pharmaceutical ingredients (APIs), metallic stearates, and herbal extracts. The facility is strategically located with easy access by air, sea, road, and rail, facilitating efficient distribution to both domestic and international markets.

3Key Leadership

The leadership team at S Kant Healthcare Limited comprises:

Bharat Nemchand Shah: Director
Samir Jayantilal Shah: Director
Ritesh Bipin Shah: Director
Rohan Mahesh Shah: Director
Gaurav Satish Shah: Director
Mahesh Harishchandra Kolambe: Director

These individuals bring a wealth of experience and strategic vision to the company, driving its growth and global expansion.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does S Kant Healthcare Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

S Kant Healthcare Limited has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facility holds EU-GMP certification, ensuring compliance with stringent European standards. Additionally, the plant has received approvals from various Ministries of Health, such as Ghana-FDA, Kenya-P&PB, Nigeria-NAFDAC, and Uganda-NDA, facilitating market access in these regions.

2Emerging Markets

S Kant Healthcare Limited has expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company's products are available in over 80 countries, with a dedicated operational presence in regions like East Africa. The manufacturing facility's WHO prequalification enhances access to these markets, enabling the company to supply essential medicines to underserved populations.

3Geographic Strategy

S Kant Healthcare Limited demonstrates a diversified geographic strategy, mitigating concentration risk by operating in over 80 countries. The company's strategic direction focuses on expanding its global presence while maintaining a strong foothold in emerging markets. This approach ensures a balanced portfolio and resilience against regional market fluctuations.

S Kant Healthcare Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

S Kant Healthcare Limited's manufacturing facility is registered with the U.S. Food and Drug Administration (FDA), indicating compliance with U.S. regulatory standards. The company has filed multiple Abbreviated New Drug Applications (ANDAs) and Drug Master Files (DMFs), facilitating the approval of its generic formulations in the U.S. market. The facility has undergone FDA inspections, receiving favorable outcomes, which underscores its commitment to quality and regulatory compliance.

2WHO & EU GMP

The manufacturing facility holds both WHO prequalification and EU-GMP certifications, affirming its adherence to international quality standards. These accreditations enable S Kant Healthcare Limited to supply essential medicines to a global clientele, including international organizations and government agencies.

3CDSCO & Indian Regulatory

S Kant Healthcare Limited's manufacturing facility is licensed by the Central Drugs Standard Control Organisation (CDSCO), ensuring compliance with Indian regulatory requirements. The company has obtained approvals from various state drug controllers and holds export No Objection Certificates (NOCs), facilitating the export of its products to numerous countries.

S Kant Healthcare Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

S Kant Healthcare Limited operates in a competitive landscape, with key competitors in overlapping therapeutic categories such as antimalarial, antifungal, and antibiotic formulations. The company's market share in these categories positions it favorably, with a particularly strong presence in antimalarial and antiparasitic products. A head-to-head analysis reveals that S Kant's product portfolio and manufacturing capabilities provide a competitive edge in terms of quality, supply chain reliability, and regulatory compliance.

2Key Differentiators

S Kant Healthcare Limited's unique strengths include its backward integration within the SK Group, which ensures a consistent supply of APIs and finished formulations. The company's EU-GMP certified manufacturing facility and WHO prequalification further distinguish it in the market. Additionally, S Kant's extensive product portfolio across multiple therapeutic categories and its presence in over 80 countries underscore its global reach and commitment to quality.

3Strategic Position

S Kant Healthcare Limited's current strategic direction focuses on expanding its global footprint through the supply of generic pharmaceuticals, with an emphasis on essential medicines. The company's future outlook includes exploring opportunities in specialty pharmaceuticals and Contract Development and Manufacturing Organization (CDMO) services, leveraging its manufacturing capabilities and regulatory accreditations to serve a broader range of clients.

Buyer Due Diligence Brief — Evaluating S Kant Healthcare Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

S Kant Healthcare Limited has a commendable track record in manufacturing and exporting pharmaceutical products, with a total export value of $35.0 million USD and 946 shipments across 12 products in 6 therapeutic categories. The company's portfolio concentration, with the top 5 products accounting for 79.4% of exports, indicates a focused approach. Reliability indicators include its EU-GMP certification, WHO prequalification, and approvals from various Ministries of Health, reflecting consistent quality and compliance.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Registration: Confirm the facility's registration status with the U.S. FDA to ensure compliance with U.S. standards.

WHO-GMP Certification: Verify the facility's WHO prequalification to ensure adherence to international quality standards.

Frequently Asked Questions — S Kant Healthcare Limited

How many pharmaceutical products does S Kant Healthcare Limited export from India?

S Kant Healthcare Limited exports 12 pharmaceutical products across 6 therapeutic categories. The top exports are Artemether ($8.4M), Clotrimazole ($7.2M), Sulfadoxine ($5.2M), Pyrimethamine ($4.3M), Erythromycin ($2.8M). Total export value is $35.0M.

What is S Kant Healthcare Limited's total pharmaceutical export value?

S Kant Healthcare Limited's total pharmaceutical export value is $35.0M, based on 946 verified shipments recorded in Indian Customs (DGFT) data.

In which products is S Kant Healthcare Limited the #1 Indian exporter?

S Kant Healthcare Limited is the #1 Indian exporter in 2 products: Sulfadoxine (9.5% market share), Pyrimethamine (9.2% market share).

What therapeutic categories does S Kant Healthcare Limited cover?

S Kant Healthcare Limited exports across 6 therapeutic categories. The largest are Antimalarial & Antiparasitic (50.9%, 3 products), Antifungals (24.0%, 3 products), Antibiotics (13.5%, 3 products).

Get Full S Kant Healthcare Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.